303 Frequency and acceptance of CDSS-generated STOPP/START signals - SI SUPPLEMENTARY INFORMATION SI1 Table SI1.1. Frequency and acceptance of CDSS-generated STOPP/START signals in total and per country. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) TOTAL 3465 40.1% 423 39.7% 2025 34.7% 384 57.6% 633 47.2% A 1. Any drug prescribed without an evidencebased clinical indication. 1412 54.2% 156 53.8% 846 46.8% 171 76.6% 239 64.9% A 3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, anticoagulants 503 26.0% 54 31.5% 293 27.0% 51 25.5% 105 21.0% D 5. Benzodiazepines for ≥ 4 weeks 181 64.1% 54 59.3% 71 60.6% 11 90.9% 45 68.9% F 2. PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 weeks 146 34.9% 13 38.5% 81 28.4% 28 46.4% 24 41.7% B 6. Loop diuretic as first-line treatment for hypertension . 101 22.8% 8 0% 71 18.3% 8 25.0% 14 57.1% C 3. Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors with concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial spontaneous bleeding) 75 4.0% 2 0% 71 4.2% 2 0% 0 0% F 3. Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs, oral iron, opioids, verapamil, aluminium antacids) in patients with chronic constipation where non-constipating alternatives are available 75 20.0% 6 16.7% 38 7.9% 13 30.8% 18 38.9% 4
RkJQdWJsaXNoZXIy MTk4NDMw